Výsledky vyhledávání - Rustem Gafanov

  • Zobrazuji výsledky 1 - 9 z 9
Upřesnit hledání
  1. 1
    KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

    KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer Autor Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R Chandana, Ben Li, Joseph E. Burgents, Karim Fizazi

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

    Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Autor David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, Przemysław Langiewicz, В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Fréderic Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

    669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study Autor Rustem Gafanov, T.B. Powles, Jens Bedke, V.P. Stus, Tom Waddell, Dmitry Nosov, Fréderic Pouliot, Denis Soulières, Bohuslav Melichar, Sérgio Jobim Azevedo, Ray McDermott, Ihor Vynnychenko, Delphine Borchiellini, M. Markus, Igor Bondarenko, J. Lin, Joseph E. Burgents, L. Rhoda Molife, Elizabeth R. Plimack, Brian I. Rini

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

    LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) Autor Johann S. de Bono, Sergio Bracarda, Cora N. Sternberg, K.N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Rustem Gafanov, Francis Parnis, Gary L. Buchschacher, Luis Corrales, Michael Borre, Gustavo Vasconcelos Alves, Josep Garcia, M-L. Harle-Yge, G. Chen, Matthew Wongchenko, Christopher J. Sweeney

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

    Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma Autor David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Autor Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Robert D. Hawkins, Dmitry Nosov, Fréderic Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Ray McDermott, Jens Bedke, Sophie Tartas, Yen‐Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Chen Mei, Michael B. Atkins, Thomas Powles

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

    Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEY... Autor Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae‐Lyun Lee, Niven Mehra, Ray McDermott, Núria Sala‐González, Peter C.C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Rustem Gafanov, Maria De Santis, Eli Rosenbaum, Michael Paul Kolinsky, Felipe Rey, Kun‐Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian Poehlein, Evan Y. Yu

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial Autor Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, T. J. Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean‐Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fábio Franke, Fabrício Augusto Martinelli de Oliveira, Andrea Juliana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Rosa Zucca, Giuliano Santos Borges, André M. Murad, Fred Saad, Kim N., Yves Fradet, Neil Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stéphane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean‐Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz‐Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus Johannes Maria van den Eertwegh, Johannes Voortman, Maureen J.B. Aarts, Jourik A. Gietema, Choung‐Soo Kim, Young Deuk Choi, Byung Ha Chung, Rustem Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, Pablo Maroto, Jesús García-Donás, Juan F. Rodríguez-Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, D. Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente, E.A. Castellanos Abella, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, doubl... Autor Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Goncalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, O. N. Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: